BioInvent International AB

BINV

SE0015244520

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:45 2024-05-24 EDT			5-day change	1st Jan Change
32.95 ^SEK	+3.62%		+10.02%	+73.79%

05-23	BioInvent Presents Promising Phase 1 Data for Bi-1206 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Solid Tumors	CI
05-23	BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024	CI

Bioinvent International AB Elects Kristoffer Bissessar as New Board Member

May 28, 2020 at 12:10 pm

BioInvent International AB (publ) at its AGM held on May 28, 2020, approved to elect Kristoffer Bissessar as new Board member.

Latest news about BioInvent International AB

BioInvent Presents Promising Phase 1 Data for Bi-1206 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Solid Tumors	05-23	CI
BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024	05-23	CI
Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL	05-14	CI
Bioinvent International AB Resolves to Elect Laura Lassouw-Polman as New Board Member	05-03	CI
BioInvent Announces Evaluating Attana Technology	04-30	CI
BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	04-03	MT
Transcript : BioInvent International AB, 2023 Earnings Call, Feb 22, 2024	02-22
BioInvent International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
BioInvent International AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
BioInvent International AB Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607	12-05	CI
Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910	12-05	CI
BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent	11-03	CI
BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910	23-10-31	CI
Transcript : BioInvent International AB, Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
BioInvent International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Global markets live: Nvidia, Chevron, FedEx, Roche, PepsiCo...	23-10-10
Transgene and BioInvent International AB Announces First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA	23-10-10	CI
BioInvent International Enrolls First Patient for Phase 2a Trial of Cancer Therapy	23-09-22	MT
Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies	23-09-22	CI
BioInvent International AB(OM:BINV) dropped from S&P Global BMI Index	23-09-18	CI
BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors	23-09-08	CI
BioInvent International To Receive $1 Million Milestone Payment in Exelixis Research Deal	23-09-07	MT
Bioinvent International AB Achieves Research Milestone Event in Its Exclusive Option and License Agreement with Exelixis, Inc	23-09-07	CI
BioInvent International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI

Chart BioInvent International AB

Duration

Period

More charts

BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Meeting - Abstract Number: 2641

More about the company

Income Statement Evolution

More financial data

Ratings for BioInvent International AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

32.95 SEK

Average target price

83 SEK

Spread / Average Target

+151.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOINVENT INTERNATIONAL AB	+73.79%	204M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs